RPRX Insider Trading

Insider Ownership Percentage: 18.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Royalty Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Royalty Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal Insider BuyingTotal Insider Selling

Royalty Pharma Share Price & Price History

Current Price: $25.75
Price Change: Price Decrease of -0.09 (-0.35%)
As of 01/6/2025 05:00 PM ET

This chart shows the closing price history over time for RPRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$25.75Closing price on 01/06/25:

SEC Filings (Institutional Ownership Changes) for Royalty Pharma (NASDAQ:RPRX)

54.35% of Royalty Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RPRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$15kbought$14MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$500M$0$500MTotal InflowsTotal Outflows
Royalty Pharma logo
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Read More on Royalty Pharma

Today's Range

Now: $25.75
Low: $25.40
High: $26.10

50 Day Range

MA: $25.95
Low: $24.28
High: $27.54

52 Week Range

Now: $25.75
Low: $24.05
High: $31.66

Volume

2,232,316 shs

Average Volume

1,945,539 shs

Market Capitalization

$15.17 billion

P/E Ratio

13.34

Dividend Yield

3.26%

Beta

0.47

Who are the company insiders with the largest holdings of Royalty Pharma?

Royalty Pharma's top insider shareholders include:
  1. Avara Management Ltd (Major Shareholder)
  2. Rory B Riggs (Director)
  3. Terrance P Coyne (CFO)
  4. Pablo G Legorreta (CEO)
  5. George W Lloyd (EVP)
  6. Marshall Urist (EVP)
Learn More about top insider investors at Royalty Pharma.

Who are the major institutional investors of Royalty Pharma?

Royalty Pharma's top institutional investors include:
  1. Nordea Investment Management AB — 0.00%
  2. GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of Royalty Pharma stock.

Which major investors are selling Royalty Pharma stock?

During the last quarter, RPRX stock was sold by these institutional investors:
  1. Nordea Investment Management AB

Which major investors are buying Royalty Pharma stock?

During the last quarter, RPRX stock was acquired by institutional investors including:
  1. GAMMA Investing LLC